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A B S T R A C T   
To improve the oral absorption of fish oil and test its anti-inflammatory effect, a fish oil nanoemulsion was 
developed using cis-4,7,10,13,16,19-docosahexaenoic fatty acid as a biomarker for oral administration. The 
colloidal stability tests of the fish oil nanoemulsion showed an average size of 155.44 nm ± 6.46 (4 ◦C); 
163.04 nm ± 9.97 (25 ◦C) and polydispersity index 0.22 ± 0.02 (4 ◦C), 0.21 ± 0.02 (25 ◦C), indicating systems 
with low polydispersity and stable droplets. The fish oil nanoemulsion did not alter the cell viability of the RAW 
264.7 macrophages and, at a concentration of 0.024 mg/mL, was kinetically incorporated into the cells after 18 h 
of contact. The nanoemulsion was maintained in the gastrointestinal region for a significantly shorter period of 
time (p ≤ 0.05) compared to the intake of fish oil in free form. Inflammatory tests demonstrated that nano-
emulsion and fish oil showed less (p ≤ 0.05) neutrophil infiltration after 24h of sepsis induction and there was a 
significant reduction (p ≤ 0.05) in the volume of paw edema in female adult Balb/c mice who received the 
nanoemulsion diet compared to the other experimental groups (control, formalin, fish oil and sunflower oil). 
These results indicate that the fish oil nanoemulsion was significantly effective in the dietary conditions tested 
here, presenting satisfactory responses in the modulation of inflammatory disorders, demonstrating interesting 
and beneficial nutraceutical effects.   
1. Introduction 
In the inflammatory process, ɷ-3 and ɷ-6 fatty acids act in the 
modulation of inflammatory reactions, producing biologically active 
mediators called eicosanoids with different stereochemistry [1–6]. The 
most important types of omega-3 are fatty acids, such as cis-4,7,10,13, 
16,19 docosahexaenoic (DHA) and cis-5,8,11,14,17 eicosapentaenoic 
(EPA), which usually produce mediators of low inflammatory potential. 
On the other hand, omega-6 fatty acids, such as arachidonic acid (AA), 
are used as a substrate to produce high-potential inflammatory eicosa-
noids, such as series-2 prostaglandins (PGE2) and series-4 leukotrienes 
(LTB4) [7,8]. 
When an injury occurs in the cell membrane, inflammation begins 
after the production and release of these fatty acids that are produced 
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from the membrane phospholipids, and the initial events of the 
inflammation occur through the AA cascade. In this metabolic pathway, 
oxidation of AA is initiated by the synthesis of lipid mediators. This 
process occurs through different mechanisms in the pathways: cyclo-
oxygenase (COX), 5-lipooxygenase (5-LOX) (or 15-lipooxygenase and 
12-lipooxygenase) and cytochrome P450. [6,9–13]. 
AA and EPA compete for the same receptors in the enzymatic path-
ways of COX and LOX. When EPA is used as substrate, it is possible to 
observe a decreased production of eicosanoids with high inflammatory 
potential. Thus, contributing to the synthesis of eicosanoids with low 
inflammatory potential of series 3 and 5 (odd), such as; prostaglandins 
(PGE3), leukotrienes (LTB5) and thromboxanes (TXA3) [1,10,14–17]. 
By simultaneous action on the COX and LOX pathways, EPA and DHA 
are involved in the production of E series resolvins (from EPA) and D 
series resolvins, protectins, and maresins (from DHA), which are medi-
ators that have strong anti-inflammatory potential acting in the reso-
lution of inflammation [1,10,14–17]. 
The first key point of this work is that mammals are not able to 
naturally synthesize omega-3 polyunsaturated fatty acids, such as EPA 
and DHA, and eventually these acids must be obtained from the diet, 
mainly from some natural source rich in these fatty acids, such as fish oil 
(FO). The direct relationship of the anti-inflammatory effect of fish oil is 
strictly related to the mechanism of action of DHA and EPA, as presented 
in the previous paragraphs. 
The second key point that will be addressed in this article is that most 
nutritional products produced from fish oil are highly hydrophobic 
products that, according to the literature [7,18], are poorly absorbed 
orally due to their limitation of low solubility in water. The oral 
bioavailability of DHA and EPA fatty acids in FO sources is strongly 
linked to solubilization in the gastrointestinal tract, and their lipid 
structure can influence their bioavailability [18]. 
To circumvent this disadvantage, our research group has been 
involved in projects with Nanotechnology to improve absorption and 
reduce the gastric emptying time of this type of lipophilic compound 
[19]. The idea is to disperse lipophilic compounds, such as FO, in stable 
nanodroplets. In this way, the loaded components can easily cross the 
mucous barrier, which is the main obstacle for lipid molecules, and 
reach the cell layer of the membrane to be absorbed [20]. Gastrointes-
tinal mucus is a complex system that also acts as a selective physical 
barrier, allowing the rapid passage of small molecules [20,21]. Thus, the 
forms of delivery of a formulation must be designed with functional 
properties to adhere to the mucous membranes, allowing better 
absorption. 
In this context, we designed the development of a nanoemulsified 
system for the release of lipophilic compounds, such as FO. Our main 
objective was to test whether the oral administration of a fish oil lipid 
nanoemulsion could improve the absorption of FO in experimental 
models in vivo, thus increasing the availability of anti-inflammatory 
omega-3 fatty acids. Thus, our hypothesis was that, based on the 
availability of DHA and EPA in the nanoformulated diet, oral supple-
mentation with fish oil nanoemulsion (NEW3) could modulate the in-
flammatory response in experimental animals compared to animals 
treated with conventional FO. 
2. Materials and methods 
2.1. Methodological steps 
To answer the hypotheses of this investigation, the following steps 
were planned in this study: (1) development and characterization of the 
colloidal stability of the NEW3 nanoemulsion; (2) evaluation of cyto-
toxicity and kinetics of in vitro incorporation of NEW3 nanoemulsion in 
mammalian cells; (3) in vivo evaluation of gastric emptying time of 
NEW3 nanoemulsion and free fish oil; (4) in vivo evaluation of the anti- 
inflammatory effect of the NEW3 oral diet (supplementation) in two 
experimental models. 
2.2. Materials and reagents 
Omega 3 fish oil capsules (Nu3 Health DHA-500) containing a 
mixture of DHA and EPA (DHA 0.5 g; EPA 0.1 g) obtained commercially 
from Natue Trade in Food Products, Ltda and natural oil from babassu 
(BBS) obtained from a local shop were tested in the oil phase nano-
emulsion. Milli-Q ultrapure water was used as a vehicle in the formu-
lation and the Solutol HS 15-polyoxyethylene esters of 12- 
hydroxystearic acid (Sigma-Aldrich, USA) used as an emulsifier. 
Commercially available sunflower oil (composed of 0.58 g of poly-
unsaturated fats/48–74 % linoleic acid), 1 mg/mL of lipopolysaccha-
rides (LPS), luminol (30 mg/mL), formalin (2.5 %) and sodium chloride 
(NaCl) (0.9 %) were used to study experimental in vivo models of 
inflammation. Other reagents were needed in the course of the experi-
ments: all-cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester stan-
dard, 99.9 % purity, (Sigma-Aldrich, USA), HPLC grade methanol, 
Phosphate-saline buffer (PBS), DMEM (Dulbecco’s Modified Eagle Me-
dium, 1,1′-dioctadecyltetramethyl indotricarbocyanine iodide -XDIR 
(Caliper Life Sciences, USA), 1%. 
2.3. Development of fish oil nanoemulsion (NEW3) 
The nanoformulations were developed using the Phase Inversion 
Temperature method available and recommended in the literature [22, 
23] with adaptations. Fish oil was formulated considering the concen-
tration of DHA and EPA; these concentrations of DHA and EPA as well as 
the other components used in the formulations were per mg/mL of 
emulsion and are available in Table 1. 
To obtain the final formulation of fish oil (NEW3), screening was 
carried out based on the production of six nanoemulsions (Nano A, Nano 
B, Nano C, Nano D, Nano E and Nano F) (Table 1). At this stage, the 
Hydrodynamic Diameter (nm) and the Polydispersion Index (PDI) were 
evaluated over time, at 01 (after 24 h) and 30 days (Supplementary 
Fig. S1), and visual observations of the macroscopic characteristics, 
namely phase separation and color change, were performed. 
The oily phases were tested, using fish oil and babassu oil (BBS). The 
aqueous phase was composed of Milli-Q Ultrapure Water (18 MΩ.cm), 
and the emulsifier used was Solutol HS 15-polyoxyethylene esters of 12- 
hydroxystearic acid (Sigma-Aldrich, USA). These components were 
chosen because of the ease in forming nanoemulsions with low energy 
demand. 
A blank nanoemulsion (NE-blank) without fish oil from the final 
formulation was also prepared, following the same experimental pro-
cedures for comparison purposes in cell culture experiments. For the 
study of the characterization and colloidal stability, NEW3 samples were 
protected from light radiation and stored under two temperature con-
ditions, 4 ◦C and 25 ◦C. 
For in vitro tests using mammalian cells (RAW 264.7 macrophages) 
and in vivo tests in mice, the nanoemulsion was filtered using a sterile 
filter, coated with a 0.22 μm pore size membrane, non-pyrogenic (Kasvi, 
K18− 230). Subsequently, the size was measured by Dynamic Light 
Table 1 
Nanoformulations of Fish Oil (FO) and concentrations (mg/mL) of the 
components.  















DHA 6.25 3.125 6.25 3.125 1.5625 1.5625 
EPA 1.25 0.625 1.25 0.625 0.3125 0.3125 
Solutol HS15 18 18 32.5 32.5 18 20 
Castor Oil – – – – – 10 
BBS 5 5 5 5 5 5 
DHA: cis-4,7,10,13,16,19 docosahexaenoic acid; EPA: cis-5,8,11,14,17 eicosa-
pentaenoic acid; BBS: Babassu oil; d =1 g/cm3 para 20 g de H2O q.s.p. Author 
search data (2017). 
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Scattering (DLS) (Supplementary Fig. S2). In in vivo tests, the thera-
peutic concentration tested was 50 mg/Kg DHA and 10 mg/Kg EPA per 
animal/day according to the recommendation of global oral intake 
[24–27]. 
2.4. Colloidal characterization and stability 
2.4.1. Droplet size analysis 
Droplet size and PDI were analyzed at different times (1, 7, 15, 30, 
60, 180 and 338 days) after nanoemulsion preparation. The nano-
emulsions were evaluated at two temperatures, 4 ◦C and 25 ◦C. The 
samples were diluted 1:20 (v/v) in Milli-Q ultrapure water (18 MΩ.cm) 
and measured by Dynamic Light Scattering (DLS) [28,29] using Zeta-
sizer Nano (ZEN3690 model, Malvern Instruments, United Kingdom). 
2.4.2. Determination of zeta potential 
The zeta potential was measured after 1, 7, 15, 30, 60 and 180 days 
and evaluated at two temperatures, 4 ◦C and 25 ◦C. The formulation was 
diluted 1:20 (v/v) in ultrapure water Milli-Q (18 MΩ.cm) and analyzed 
using Zetasizer Nano (model ZEN3690, Malvern Instruments, United 
Kingdom). Smoluchowski’s model was used to calculate the zeta po-
tential of the systems [30]. 
2.4.3. pH measurement 
The pH values of nanoemulsions were measured after 01, 07, 15, 30, 
60 and 180 days at two temperatures, 4 ◦C and 25 ◦C. A pH meter was 
used, accuracy ± 0.01, sensitivity 100 % (NTPHM model, New Tech-
nology, Brazil), calibrated with standard solutions at pH 4.0 and pH 7.0, 
and the samples were diluted 1:10 (v/v) in Milli-Q ultrapure water 
(18 MΩ.cm) [31,32]. 
2.4.4. Scanning electron microscopy – SEM 
Visualization of morphology of fish oil nanoemulsion was carried out 
by Transmission Scanning Electron Microscopy (SEM). An Electron 
Scanning Microscope (Jeol, JSM-7000 F, US) coupled to an EDS system 
(NSS 2.2 X-Ray MicroAnalysis, Thermo Scientific, US) was used. The 
samples were diluted 1:500 (v/v) in Milli-Q ultrapure water, and 100 μL 
of the dilution was deposited on a smooth and polished iron stub surface. 
The samples were contrasted with 2% OsO4 vapor for 30 min to label the 
lipids and left overnight to dry samples at room temperature. After 
complete drop drying, nanoemulsion was metallized with Platinum film 
on a Sputter Coater (Balzers SCD 50, USA). The images were collected at 
an increase of 10,000 x with 15.0 kv. 
2.4.5. Preparation of the DHA calibration curve and quality control 
To obtain the DHA standard calibration curve, triplicate solutions of 
the all-cis-4,7,10,13,16,19 docosahexaenoic acid methyl ester standard, 
99.9 % purity, (Sigma-Aldrich, USA) in concentrations of (0; 0.01; 
0.025; 0.04; 0.055 mg/mL) diluted in HPLC grade methanol were pre-
pared for the standard curve (Supplementary Fig. S3). High perfor-
mance liquid chromatography (HPLC) was used, with a chromatograph 
(Shimadzu-Prominence series 20 Model) coupled to a degasser (DGU 
20A5), automatic sampler (SIL-20AHT), pump (LC-20AT), column oven 
(CTO-20A) and CBM- Controller 20A. The detector used was UV–vis 
(SPD-20A) and a wavelength adjusted to 210 nm. 
The stationary phase consisted of a Kinetex C18 column 
(25cm × 0.4cm/5 μm of particle diameter) (Phenomenex), oven tem-
perature of 30 ◦C. The mobile phase consisted of 88 % HPLC grade 
methanol; the analysis was performed with a flow of 1 mL/min, isocratic 
method, sample injection volume of 20 μL and 25 min. Data processing 
was performed using the LC Solution V 1.24 software (Shimadzu, Tokyo- 
Japan). 
The quality control samples of nanoemulsion (NEW3) and fish oil 
(FO) were methylated in basic catalysis using methods adapted from ISO 
5509 International Organization for Standardization [33] and Milinsk 
et al. [34] for obtaining the methyl esters of docosahexaenoic acid. The 
quantification of DHA (mg/mL) in the test samples was analyzed by 
HPLC adapted from Kotani et al. [35] and Salm et al. [36] in methanol 
and water (88:12 v/v) to confirm the presence of DHA. The concentra-
tions of the methylated test samples were 0.001998 mg/mL for the 
NEW3 nanoemulsion and 0.03798 mg/mL for fish oil. 
2.4.6. Raman measures 
Raman microspectroscopy analyses were performed using LabRAM 
HR Evolution (HORIBA Scientific, Palaiseau, France) equipped with an 
1800 lines/mm grating and CCD detector. Measurements were con-
ducted with a 532 nm laser excitation source (10 mW) focused on the 
samples by an OLYMPUS microscope with a 50× objective. 
2.5. In vitro cell experiments 
2.5.1. Cell culture 
The RAW 264.7 adherent murine macrophage lineage, immortalized 
from the ATCC American Type Culture Collection, Rockville, MD, USA, 
was used for this study. The cells were thawed at room temperature and 
expanded in 250 mL cell culture flasks, with sterile filter and 75 cm2 
growth area (Greiner bio-one, São Paulo, BR) in sterile DMEM medium 
(Gibco® Life Technologies, Ltd, USA), buffered with sodium bicarbonate 
(NaHCO3), pH 7.2, supplemented with 10 % (v/v) Bovine Fetal Serum 
(SFB) (Gibco® Invitrogen ™, USA) and 1% (v/v) of Pen Strep antibiotic 
solution (Gibco® Invitrogen ™, USA) composed of 100 IU/mL penicillin 
+ 100 μg/mL streptomycin. The cells were cultured and kept in an 
incubator oven at a temperature of 37 ◦C, an atmosphere of 95 % hu-
midified air and 5% CO2 until the formation of the cell monolayer rea-
ches the confluence. The cells were detached from the flask surfaces by 
scraping using a squeegee of sterile polyethylene cells, non-pyrogenic 
and non-cytotoxic, and then centrifuged at 178.88 g RCF for 3 min, 
followed by resuspension in DMEM medium. 
2.5.2. Real-time cell analysis (RTCA) of cytotoxicity 
The real-time effects of NEW3 nanoemulsion and blank nano-
emulsion (NE-blank) on murine macrophage cells (RAW 264.7) were 
monitored using the RTCA-DP system (xCELLigence, Roche Applied 
Science). The cells were grown in cell culture flasks until they reached 
80 % confluence and then were seeded at 2.5 × 103 cells/well in two 16- 
well plates (E-Plate16) containing electronic biosensors to measure 
impedance generated by cell adhesion. 
The RTCA experiment consisted of 3 main steps: (1) 50 μL of DMEM 
culture medium (at room temperature) was added to all wells and 
maintained for 30 min for calibration and verification of the correct 
electrode function; (2) 50 μL of cells were added to the wells to wait for 
diffusion scattering, and the plates were incubated for 24 h before 
treatment; (3) Then, the culture medium of each well was carefully 
discarded with the aid of calibrated micropipettes in the laminar flow 
cabinet; after disposal, the cells were treated with 150 u L of fresh me-
dium containing the test samples, the plates were returned to the oven at 
37 ◦C with 5% CO2, and monitoring was started and maintained for up to 
72 h. 
The mapping of treatments with RAW 264.7 cells were: T1-NEW3: 
0.048 mg/mL; T2-NEW3: 0.097 mg/mL; T3-NEW3: 0.120 mg/mL; T4- 
NE-blank: 0.048 mg/mL; T5-NE-blank: 0.097 mg/mL; T6-NE-blank: 
0.120 mg/mL. Each experimental sample was analyzed in triplicate. 
The untreated RAW 264.7 cells served as a negative control. 
2.5.3. Kinetics of DHA incorporation into macrophages 
To evaluate the kinetics of DHA incorporation in RAW 264.7 
macrophage cells the following steps were performed: a) plating at a 
concentration of 5.0 × 103 cells/well in two 24-well plates; b) cell 
growth for 24 h; c) treatment with fish oil nanoemulsion samples 
(NEW3) in concentrations of 0.024 mg/mL and 0.048 mg/mL; finally, 
the control consisted of untreated cells. The samples were monitored 
over time; 17, 18 and 19 h; d) Then, extraction of free DHA from the 
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monolayer of RAW 264.7 cells was performed with isopropyl alcohol P. 
A (Sigma-Aldrich, USA). 
The DHA (mg/L) extraction step occurred as follows: I) the medium 
was removed from each well and 1 mL of P.A. isopropyl alcohol (Sigma- 
Aldrich, USA) was added. The system remained in an environment 
saturated with the isopropyl alcohol solvent P.A overnight; after that, 
the solvent was collected from each well and evaporated with N2 vapor. 
II) after evaporation, the samples were resuspended in 1 mL of HPLC 
grade methanol and transferred to previously identified Eppendorf tubes 
and centrifuged for 10 min at 2236 g RCF. III) the supernatant was 
collected and measured using the HPLC technique. The samples were 
analyzed in triplicate (n = 3), and the operational parameters are similar 
to those described in item 2.4.5. 
2.6. In vivo experiments 
To answer the question of whether oral administration of a fish oil 
nanoemulsion (NEW3) reduces gastric emptying time and, conse-
quently, improves the absorption of FO, thereby increasing the avail-
ability of anti-inflammatory omega-3 fatty acids in membrane 
phospholipids, thus mediating inflammatory processes, we applied 
studies to experimental models in vivo. First, we observed the gastric 
emptying time in two independent experiments and second, we 
analyzed the effect of NEW3 in two inflammatory models. 
2.6.1. Ethics statement 
This study was approved by the Animal Use Ethics Committee 
(CEUA) of the University of Brasilia under protocol no. 7/2017 (CEUA- 
UnB-7/2017) and respects the National Ethical Standards in accordance 
with Federal Law 11.794 of October 08, 2008 [37], and the resolutions 
of the National Council for Control of Animal Experimentation 
− CONCEA (BR) [38], and other international standards applicable to 
the use of animals for teaching and research, in particular the UK Animal 
Law (Scientific Procedures) 1986 and associated guidelines [39], 
ARRIVE guidelines. 
2.6.2. Animal model 
The animal model used consisted of healthy adult female isogenic 
mice, Mus musculus, Balb/c, aged between 10 and 12 weeks and with a 
body mass of approximately 16.0–31.0 g. The animals were supplied by 
the central vivarium of the Pontifical Catholic University of Brasilia 
(Brazil) and kept in the vivarium of the Department of Genetics and 
Morphology (UnB, Brazil) in polypropylene cages (30 × 20 × 13 cm) 
covered with stainless steel ASI wire. The cages were cleaned and 
sanitized three times a week and were kept in a low-speed, continuous 
airflow system, with excellent air exchange and internal pressure bal-
ance. The mice were kept at a controlled temperature (22 ◦C ± 2 ◦C) 
with a 12/12 -h light/dark cycle, with ad libitum water supply and 
controlled purine pelleted feed. 
2.6.3. In vivo experimental groups 
For the gastric emptying time model, three (3) experimental groups 
were tested: (I): XDIR, (II): fish oil (FO) and (III): NEW3, with n = 5 
animals/group. For the first model of Inflammation, namely Sepsis 
induced with bacterial lipopolysaccharides (LPS), four (4) experimental 
groups were tested; (I): PBS control, (II): NEW3, (III): fish oil (FO) and 
(IV): sunflower oil (SO), each group with n = 5 animals. For the second 
model of inflammation, which was Paw Edema induced with Formalin, 
five (5) experimental groups were tested; (I): PBS control (Saline), (II): 
Formalin (FM), (III): sunflower oil (SO), (IV): fish oil (FO) and (V): 
NEW3, all with n = 7 animals/group. 
2.6.4. Oral diet - treatments (doses) 
For each experimental group of the gastric emptying test, 200 μL of 
the sample diluted in sterile PBS was administered orally (gavage) 
corresponding to a single dose for each treatment: group (I) XDIR with 
57.36 mg/Kg of XDIR; group (II) Fish oil (FO) with 100 mg/Kg of FO 
(containing 50 mg/Kg of DHA and 10 mg/Kg of EPA) and group (III) 
nanoemulsion of fish oil (NEW3) with 100 mg/Kg of NEW3 (containing 
50 mg/Kg of DHA and 10 mg/Kg of EPA). These doses were adminis-
tered before the visualization procedures using the in vivo imaging 
technique. The group of labeled fish oil (FO) comprised the control 
sample. 
For the two experimental models of Inflammation (Sepsis and Paw 
Edema) the groups NEW3, FO and SO received a daily dose of 100 mg/ 
Kg of NEW3 (containing 50 mg/Kg of DHA and 10 mg/Kg EPA), 100 mg/ 
Kg of FO (containing 50 mg/Kg of DHA and 10 mg/Kg EPA) and 
100 mg/Kg of SO (containing 58 mg/Kg of polyunsaturated fats/higher 
% linoleic acid), respectively. 
It is important to highlight that for these models the daily doses of 
the diet with source of omega 3 fatty acids were based on the concen-
trations of DHA 6.25 mg/mL and EPA 1.25 mg/mL contained in 
12.5 mg/mL of oil of fish, and source of omega 6 in the concentration of 
7.30 mg/mL of polyunsaturated fats/higher% of linoleic acid contained 
in 12.5 mg/mL of sunflower oil. These concentrations were diluted in 
sterile PBS and administered orally by the gavage method for 21 days. 
The animals were supplemented daily, at the same time at 2 pm, with 
each sample according to the experimental group. 
The time of administration and doses applied were established based 
on global recommendations for the intake and supplementation of 
sources of polyunsaturated fatty acids and studies of the composition of 
these acids in mammalian tissues [24–27]. Before performing the 
treatments on the inflammation models, the gastric emptying time 
experiment of the NEW3 nanoemulsion and fish oil (FO) was carried out 
according to the method described below. 
2.6.5. Stomach emptying time 
This experimental protocol evaluated the emptying time of the 
stomach for the NEW3 and fish oil (FO) samples, with fasting animals 
(12 h) and fed animals (two independent experiments with an interval of 
one week between tests) with free access to water (ad libitum) and 
controlled feed. 
The samples of each treatment corresponding to the experimental 
groups (I): XDIR, (II): fish oil (FO) and (III): NEW3 with n = 5 animals/ 
group were marked with a fluorescent lipophilic 1,1′-dioctadecilte-
tramethyl indotricarbocyanine dye (XenoLight DiR) (Caliper Life Sci-
ences, USA) in the concentration of 7.17 mg/mL, 1% (w/w) of the total 
lipids, referred to in the present work as XDIR. 
Before the collection of images, the animals were treated with a 
single dose of 200 μL of the corresponding sample per experimental 
group. To collect the images, the experimental mice were anesthetized 
with isoflurane gas for 30 s and observed with fluorescence images in 
vivo IVIS Lumina XR, Version 4.3.1 (Caliper Life Sciences, USA). Quan-
tification was collected 0.5, 2, 4, 6 and 24 h after application of the 
samples. The acquisition parameters were: excitation and emission at 
720 and 790 nm, respectively; Field of view (FOV): C, Subject height 
(SH): 1.50 cm, Image mode: fluorescent photography, image (photog-
raphy) p = 2–8, high lamp level and the photons quantified in average 
radiance [p/s/cm2/sr]. 
2.6.6. LPS-induced sepsis model 
Sepsis induction was performed with LPS - gram negative bacteria 
lipopolysaccharide (Merck Millipore), for which the animals received a 
50 μL subcutaneous dorsal injection at a dose of 2 mg/Kg LPS (1 mg/ 
mL). At 2 h and 24 h after the inflammatory challenge, the animals were 
evaluated for the expression of the myeloperoxidase enzyme (MPO) 
using the in vivo bioluminescence technique. This enzyme is predomi-
nantly expressed in neutrophils [40], and the inflammatory evaluation 
in this model was related to neutrophil infiltration. The survival profile 
up to 48 h after induction was also assessed. 
For imaging, the animals were anesthetized with isoflurane (1.5–2 
%) gas for 30 s and received a 250 μL intraperitoneal injection at the 
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dose 300 mg/Kg of luminol (30 mg/mL), which is sensitive to myelo-
peroxidase (MPO) activity [41]. The data in vivo were quantified by 
extension of the photons generated in average radiance [p/s/cm2/sr] 
and acquired through IVIS Lumina XR, Version 4.3.1 (Caliper Life Sci-
ences, USA). The operating parameters were: Figure Exposure: 60 s; 
Sequence: 30 photos/1 min; Binning: 8; F/Stop: 1; Excitation Filter: 
block; Emission Filter: open and field of view (FOV): D, Subject Height 
(SH): 1.50 cm, Imaging Mode: luminescent photography, image 
(photography) p = 2–8, Focus: use subject height. 
2.6.7. Formalin-induced inflammation model paw edema 
For the second challenge of experimental inflammation, a sodium 
chloride saline solution (NaCl) (0.9 %) was prepared and applied to the 
Control (Saline) group, and this solution constituted the negative con-
trol. A Formalin solution (2.5 %) was prepared and applied to the group 
FM (Formalin) as a positive control. In these two groups, PBS was 
administered during the supplementation period. The treated groups: 
SO (sunflower oil), FO (fish oil) and NEW3 were tested, and the paw 
edema model was induced with formalin. Before induction, the animals 
were anesthetized with an intraperitoneal injection of 100 μL of a 
mixture of 10 % Xylazine Hydrochloride and 10 % Ketamine Hydro-
chloride in distilled water; after anesthesia, the basal measurement of 
the right and left paws was performed with a paw volume meter, Ple-
tysometer (Bonther, Brazil). 
Then, edema was induced in the mouse’s right hind leg with a sub-
plantar (subcutaneous) injection of 50 μL of formalin (2.5 %) [42] in the 
groups: FM, SO, FO and NEW3. The saline control group received a 
subplantar injection of NaCl (0.9 %). The volume of the paw of the mice 
was measured three times on the plethysmometer at times: 0, 15, 30, 45 
and 60 min. The percentage of increase in the volume of paw edema was 
calculated based on the formula: 
Paw volume (% increase) =
Va − Vb
Vb
x 100  
Where Va is the average paw volume at specific time intervals and Vb is 
the average paw volume before formalin injection. 
2.6.8. Quantification of prostaglandins E2 (PGE2) in tissue 
The right paws with edema were collected to quantify the concen-
tration of prostaglandins PGE2. For the extraction of prostaglandins, the 
subplantar region of the paw was collected, weighed and transferred to 
1.5 mL microtubes, previously weighed. Then 1 mL of the 0.1 M ho-
mogenization buffer of anhydrous monobasic potassium phosphate, pH 
7.4, containing 1 mM EDTA and 10 μM indomethacin was added per 
gram of tissue to the tubes. 
Then, the tubes were homogenized and centrifuged at 8000 g of RCF, 
at 18 ◦C for 10 min. The supernatant was collected and the concentration 
(pg/mL) of the PGE2 analyte was performed by means of a competitive 
immunoassay test with labeled PGE2 antibody. The assay is based on the 
competition between the PGE2 analyte contained in the standard or on 
sample between the PGE2 conjugated to the Alkaline Phosphatase 
(PGE2-AP) with an amount of mouse monoclonal antibody specific for 
PGE2. The plate is pre-coated with an anti-mouse IgG antibody. All assay 
procedures were in accordance with the instruction manual available in 
the PGE2 ELISA KIT (Invitrogen, Thermo Fisher Scientific, Austria). 
2.6.9. Hematological and tissue testing 
An aliquot of the blood of the mice from the experimental groups of 
the paw edema model was collected to quantify the hematological in-
dexes. The blood was transferred to tubes with anticoagulant and the 
analyses were measured on the hematimeter (LabTest, Brazil), where the 
following parameters were read: Erythrogram [RBC = total red blood 
cell count (x106/μL), HGB = hemoglobin concentration (g/dL), 
HCT = hematocrit percentage (%) and PTL = platelets count (x103/μL)]. 
Leukogram [WBC = total white blood cell count (x103/μL), W- 
SCC = absolute small white blood cell count - lymphocytes (x103/μL); 
W-MCC = intermediate cell count - monocytes (x103/μL) and W- 
LCC = large cell count - neutrophils (x103/μL)]. 
2.6.10. Clinical essays 
During the period of supplementation with experimental treatments 
in the two models of inflammation, the feed was controlled and supplied 
with a specific amount of 200 g per group. Every seven days, the 
resulting feed mass was collected and weighed per group, and again 
another feed batch was replaced. The animals were also weighed indi-
vidually every seven days and were evaluated for clinical aspects: body 
mass (g) and individual mass gain (g/d) calculated using the formula: 
individual mass gain (g/d) =
Mf − Mi
T  
Where: Mf is the final average mass of the animal in grams (g); Mi is the 
average initial mass of the animal in grams; T is the supplementation 
time in days. The feed efficiency was determined by means of the feed 
efficiency coefficient (CEA), which is the relationship between the mass 





Where: MFs is the animal’s final mass after the experiment (supple-
mentation) in grams (g), MIs is the animal’s body mass at the beginning 
of the experiment (supplementation) in grams (g); QTA is the total 
amount of food consumed in the experiment period in grams (g). In 
addition to these parameters, visual observations of animal mobility and 
survival profile were also performed. 
2.7. Statistical analysis 
The results collected in the present study were evaluated considering 
the value of p with the significance level of p≤0.05 from the statistical 
analysis of multiple comparison, ANOVA. The in vivo statistical planning 
for the sample size (n) was calculated based on the formula regulated by 
the Animal Use Ethics Committee of the University of Brasília (CEUA/ 
UnB), considering the power of the 90 % test and the level of significance 
p ≤ 0.05. The mean standard deviations were plotted, in which values of 
*p ≤ 0.05 were considered statistically significant; the graphs were 
produced using the GraphPad version 6.0 biostatistics program 
(GraphPad, United States of America). 
3. Results and discussion 
3.1. NEW3 preparation 
The final FO nanoemulsion was defined here as NEW3, due to the 
presence of Omega-3 in the sources of FO; it was established after 
evaluating screening and stability for one month of six different nano-
emulsion preparations. The difference in each formulation was the oil/ 
surfactant ratio. A final nanoemulsion chosen from Fish Oil (FO) was 
composed of FO (12.5 mg/mL; containing 6.25 mg/mL of DHA and 
1.25 mg/mL EPA) and babassu oil (5.0 mg/mL) as an oil phase; and 
solutol (18.0 mg/mL) as a single surfactant for nanoemulsion. 
Nano A was the only sample tested that showed no signs of macro-
scopic instability and remained within the range (mean size <200 nm 
and PDI < 0.3) after one month of observation at room temperature 
(Supplementary Fig. S1) in comparison with the other samples. The 
Nano F sample presented results within the range, but it showed signs of 
macroscopic instability, such as color change, at the end of the investi-
gated time. 
Therefore, Nano A was selected to be used as the test nanoemulsion 
for the experiments and named NEW3 (fish oil nanoemulsion). The 
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NEW3 nanoemulsion also underwent size validation tests and PDI after 
filtration (Supplementary Fig. S2). The purpose of filtration in syringe 
filters with 0.22 μm membranes was to make the system as sterile as 
possible for application in in vitro experiments and in vivo. In the vali-
dation we found that there was a reduction in the size of 2.85 % for the in 
vitro samples and 27.16 % for the in vivo samples; however, no signifi-
cant differences were observed for the polydispersion index. This pro-
cedure also did not affect the identification of the DHA biomarker in the 
nanoemulsion (Supplementary Fig. S3). 
3.2. Droplet size analysis and PDI 
Fig. 1 shows the colloidal characterization of NEW3, for which we 
measured different aspects of NEW3 stability, firstly the macroscopic 
aspects were maintained during all periods analyzed without phase 
separation. In addition to macroscopic observation, we also measured 
the hydrodynamic diameter (Fig. 1A) and polydispersity index - PDI 
(Fig. 1B). 
The NEW3 nanoemulsion showed size intervals at 4 ◦C in the range 
161.455 ± 3.753 nm (1 st day) at 145.211 ± 6.617 nm (338 days) as a 
function of time, without significant changes (p ≤ 0.05); and size range 
at 25 ◦C from 161,600 ± 3498 nm (1st day) to 162,933 ± 7967 nm (338 
days). At this temperature, only a slight change in the significant size 
(p ≤ 0.05) was observed at a single time, which was 180 days. The PDI 
values at 4 ◦C were in the range of 0.234 ± 0.013 (1st day) to 0.211 ±
0.034 (338 days). At the temperature of 25 ◦C, the range found was from 
Fig. 1. Colloidal characterization of nanoformulations at 4 ◦C and 25 ◦C as a function of time. (A) Hydrodynamic diameter - DH (nm); (B) Polydispersity index - PDI; 
(C) Zeta potential (mV); (D) pH, (E) Scanning Electron Microscopy - SEM of the NEW3 nanoemulsion; (F) Scanning Electron Microscopy - SEM of blank nano-
emulsion. Legends: NEW3: nanoemulsion with fish oil; t: time. Bar graphs with different letters and asterisks (*) show a significant difference (p ≤ 0.05) when 
comparing the times between them, based on Tukey’s multiple comparison test, 2way ANOVA multiple comparisons. The data are represented as mean ± SD, n = 3. 
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0.256 ± 0.019 (1st day) to 0.185 ± 0.021 (338 days), and it was noted 
that in both temperature conditions there was a decrease (p ≤ 0.05) of 
initial value of the PDI, demonstrating that the nanoemulsion remained 
as a monodispersed system as a function of time with averages below 
0.25. 
The size results for NEW3 are in agreement with the results of Walker 
et al. [44], who studied the physical stability at 37 ◦C and fish oil 
oxidation when entrapped in nanoemulsions produced by spontaneous 
emulsification. The researchers produced nanoemulsions of fish oil 
mixed with lemon oil and found droplet size values in the range of 
96.5 ± 2.0 nm to 166.5 ± 1.8 nm. 
Another study of the properties and stability of fish oil nano-
emulsions was carried out by Nejadmansouri et al. [45], who formulated 
fish oil nanoemulsions stabilized with different mixtures of non-ionic 
surfactants (Tween 80 and Span 80) and evaluated DH at two temper-
atures (4 ◦C and 25 ◦C) for 1 month. The authors found no significant 
differences (p < 0.05) in sizes at 4 ◦C as a function of the investigated 
time, finding the range from 100 to 200 nm; however, they were able to 
observe increasing size variations in temperature at 25 ◦C at 14 days 
with intervals of 400–500 nm. 
Considering the development of new products based on this nano-
formulation, the long-term colloidal stability of NEW3 (Fig. 1A, 1B) is a 
very important discovery in our results, as the stability continued for one 
year, when evaluated at the end of 338 days under two different tem-
perature conditions. 
3.3. Zeta Potential, pH and SEM 
The values of ZP at 4 ◦C ranged from -7.381 ± 1.528 mV (1 st day) to 
-16.744 ± 1.347 mV (180 days). At a temperature of 25 ◦C, the range 
found was -7.120 ± 1.616 mV (1 st day) to -15.094 ± 10.116 mV (180 
days) (Fig. 1C). These intervals were already expected for this system. In 
the work of [44], the ZP values obtained were -1.5 mV (day 0) and - 
2.0 mV (14 days), relatively lower than those found in the present study; 
however, in both conditions, they are in agreement with the load of 
droplet surface showing negative and slightly increased over time. 
ZP is an indicator of the stability of a colloidal suspension. Systems 
that have non-ionic surfactants with high molecular weight and absolute 
values of ZP around 20 mV (in module) or lower can provide sufficient 
stabilization, due to the chemical properties of these surfactants to act 
mainly by steric stabilization. The addition of non-ionic surfactants does 
not affect the surface potential [30]. 
The NEW3 nanoemulsion pH ranges found at 4 ◦C were 
5.935 ± 0.053 (1 st day), and 4.508 ± 0.037 (180 days); for 25 ◦C they 
were 5.94 ± 0.055 (1 st day) and 3.48 ± 0.132 (180 days) (Fig. 1D). A 
study in the literature [46] with fish oil liposomes measured over 3 
months showed mean pH equivalent to 4.53 ± 0.11, corroborating the 
results found in the present study. 
Interestingly, both the dispersion pH and zeta potential measure-
ments changed slightly depending on the observation time, but these 
changes did not significantly affect the integrity of DHA in the nano-
emulsion, which was detectable for at least one year of observation 
(Supplementary Fig. S3), and the transported DHA was chemically 
protected by the structure of the nanoemulsion. These two measure-
ments (zeta potential and pH) correlate with each other, and therefore 
the PZ is pH-dependent; so the control of the ZP is possible by controlling 
the pH. 
NEW3 morphology was observed using Scanning Electron Micro-
scopy (SEM). Fig. 1E and F show the morphological aspects of NEW3 and 
the blank nanoemulsion, respectively. Notably, the droplets present in 
the samples showed an appearance with a spherical pattern, the distri-
bution of the relative frequency of the average size of the NEW3 nano-
emulsion was 134.31 ± 28.50 nm (Supplementary Fig. S4). 
Properties such as size, shape and surface charge of a particle play a 
fundamental role in cell absorption. Negatively charged spherical par-
ticles can potentially bind to cationic sites available on the surface of the 
macrophage. Furthermore, negatively charged nanoemulsions have a 
higher uptake liver macophages compared to neutral nanoemulsions or 
positively charged nanoemulsions [47]. After these first characteriza-
tion results, we proceeded to the investigation of the quality control of 
the system and subsequent biological tests. 
3.4. Quality control - Raman measures 
DHA was used as a biomarker of fish oil (FO) and the concentration 
of this fatty acid was confirmed by HPLC analysis (Supplementary Fig. 
S3) in the nanoemulsion (NEW3) and FO samples. In this assay we used 
external standardization, where analytical curves were constructed by 
comparing the areas of the DHA fatty acid to be quantified in the NEW3 
samples and the fish oil with the areas obtained from the solutions of 
known concentrations prepared from the methyl ester standard all-cis- 
4,7,10,13,16,19, docosahexaenoic. 
The linearity of the method was determined from the mathematical 
relationship y = ax + b between the measured signal and the concen-
tration of DHA in the analytical curve. The linear determination coef-
ficient (R2) was obtained to estimate the quality of the obtained curve. 
The linear correlation coefficient (r) measures the degree of association 
(covariation) between two variables and can be calculated using the 




where the value (r) is ≥ -1 and ≤ +1. The closer the 
linear correlation coefficient (r) to +1.0, the smaller the dispersion of 
the set of experimental points and the lower the uncertainty of the 
estimated regression coefficients [48]. 
In our tests, for the analytical curve of the methyl ester standard all- 
cis-4,7,10,13,16,19-docosahexaenoic - DHA we found the value of 
(r) = 0.9999; for NEW3 the value of (r) = 1.0 and for fish oil the value of 
(r) = 1.0. For each analytical curve, a model adjustment was obtained of 
99.98 % (standard), 100 % (NEW3) and 100 % (fish oil), thus helping to 
explain all the variability of the data around the averages of the samples. 
The quantification of the presence of DHA served as a quality parameter, 
as this biomarker was identified and maintained in the nanoemulsion. 
Therefore, we proceeded to assess the chemical stability of NEW3 using 
Raman measurements. 
To investigate the chemical stability of NEW3 (25 ◦C) as a function of 
preparation time, Raman measurements at t = 0, 365 and 730 days were 
performed. These results are shown in Fig. 2. Raman spectra show 
several distinct peaks that are typical for lipids. A more detailed 
assignment of the relevant signals is given in reference [49]. In Fig. 2 (a) 
the main spectral differences are observed in the vibrational regions 
associated with carbon double-bonds C = C, which are associated with 
the degree of lipid unsaturation. Highly unsaturated fatty acids derived 
from fish oils, particularly EPA and DHA, are particularly important in 
modulating the inflammatory processes [50]. 
However, DHA and EPA molecules are susceptible to auto-oxidation, 
which begins by attacking polyunsaturated fatty acid (RH) by a species 
with sufficient reactivity to remove a hydrogen atom from a methylene 
group (− CH2-) (adjacent to a double bond = CH) leading to the initia-
tion of lipid oxidation. At this stage, there is the formation of a lipid 
radical centered on methylene carbon (- •CH-), which combines with O2 
to produce the peroxyl radical (ROO•), which is even more reactive. This 
radical removes a hydrogen atom from another unoxidized fatty acid 
molecule in a chain reaction (ROO• + RH →ROOH + R•) and in this way 
propagates the oxidation reaction [50]. 
The structural occurrence of multiple double bonds in DHA and EPA 
in the presence of free radicals allows the generation of several 
oxygenated metabolites. The combination of the peroxyl radical (ROO•) 
with an abstracted hydrogen atom forms hydroperoxide (ROOH) as a 
primary product [50]. According to Derogis et al. [51], the oxidation of 
DHA leads to the formation of at least ten monohydroperoxide isomers 
(HpDHA) all containing conjugated dienes. 
As results, when lipids are oxidized, cis double bonds of hydrophobic 
chains rearrange to form trans double bonds [52,53]. Due to this fact, 
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there is a decrease in the total degree of cis unsaturation and an increase 
in the levels of the trans unsaturation. Note that this behavior can be 
observed in Fig. 2 (d), where the integrated intensity of the vibrational 
modes cis ν(C = C) (light gray - 1557 cm− 1) and trans ν(C = C) (dark 
gray - 1567 cm− 1) are highlighted. Therefore, the behavior shown in 
Fig. 2 (d) evidences that an oxidative process is present. 
In order to assess the degree of oxidation of NEW3 samples over 
preparation time, the ratios between the integrated intensities of bands 
associated with cis double bonds and the integrated intensity of marker 
bands were taken, which do not change their intensity with the degree of 
oxidation. Sadeghi-jorabchi et al. [54] found that the ratio between the 
band around 1265 cm− 1 (in-plane–C–H deformation of unconjugated 
cis double bonds - δcis( = CH)) and the one around 1300 cm-1 (in-phase 
methylene twist deformation - δt(CH2)) is highly correlated to the cis 
isomer unsaturation. 
A similar procedure can also be used for the νcis(C = C) and cis νcis( =
CH) bands found around 1557 and 3015 cm− 1, respectively. In addition, 
Jamieson et al. [53] showed that the number of cis double bonds can also 
be obtained using the intensities ratio of stretching vibrations of 









preparation time are shown in Fig. 2 (e). Fig. 2 (b), (c) and (d) show the 
zooms of spectral regions 1200–1350; 1550–1800, and 2650 – 
3100 cm− 1, associated with δcis( = CH), δt(CH2); cis, trans ν(C = C) and 
ν( = CH), ν(CH2) vibrational modes, respectively. 
These findings demonstrate that the NEW3 sample has a long-term 
chemical stability of up to 365 days; however, signals of initial chemi-
cal instability (~ 25 %) were measured after the first year of observa-
tion, reaching ~ 80 % of reduction at 730 days of observation. We 
consider that the presence in the formulation of babassu oil, a well- 
known antioxidant oil, may have contributed to the chemical stability 
of the nanocarrier. 
This antioxidant property of babassu oil has already been investi-
gated in our previous work with nanoemulsions, generating a patent 
application [55]. In addition, PUFAs in natural oils are preferably 
distributed in the TAG sn-2 position, and chemical randomization 
studies [56] demonstrate that DHA is more stable to oxidation when 
located in the sn-2 position compared to the sn-1 position. Our NEW3 
fish oil formulation composed of a higher proportion of DHA may also 
have contributed to preserving the structure of the encapsulated DHA, as 
it showed a slower process of oxidation of fish oil up to 365 days. 
3.5. In vitro cell experiments 
3.5.1. RTCA - real time cell analysis of macrophage cytotoxicity 
After the stability tests and verification of the integrity of the NEW3 
nanoemulsion, the cytotoxicity test was performed in a culture of RAW 
264.7 macrophages by analyzing the cell adhesion index (CI) in real 
time. Fig. 3A and B show the proliferation pattern of RAW 264.7 cells 
under different conditions, and the results show the monitoring of 
samples in real time in contact with the cells. 
We selected a cell lineage with monocyte/macrophage morphology, 
because it is an important cell involved in the immune system and 
because it is widely used to assess the effects of DHA and EPA on cell 
function [57–59]. As shown in Fig. 3A and B, the NEW3 and NE-blank 
treatments (blank nanoemulsion) did not impair the proliferation of 
macrophage cells. There were no statistical differences in the cell indices 
for NEW3 and NE-blank compared to the control group, presenting good 
results in terms of cell biocompatibility at the tested concentrations. 
Real-time cell index (CI) measurement is a fast-continuous moni-
toring process that has several advantages over traditional methods that 
provide data at a single point in time. This analysis is important because 
it shows a measurement of electrochemical signals directly proportional 
to the number of live cells adhered to without the use of dyes, thus 
allowing a direct and continuous measurement of cells under physio-
logical conditions. There were no changes in the CI for the treatments 
tested here when we analyzed the AUC of NEW3 (Fig. 3A) and the AUC 
of NE-Blank (Fig. 3B), so we can verify that the treatments did not show 
significant differences compared to the control. 
This approach is interesting because it demonstrates that NEW3 
treatments at concentrations of 0.048 mg/mL; 0.097 mg/mL and 
0.120 mg/mL were not cytotoxic in macrophage cells, thus presenting 
biocompatibility in the studied lineage. Thus, we carried on the study 
with the same lineage in the next assay. 
3.5.2. Kinetics of DHA incorporation into macrophages 
After cytotoxicity experiments, we evaluated the kinetics of incor-
porating DHA into the same macrophage lineage (RAW 264.7). As 
shown in Fig. 3C, DHA was incorporated by the RAW 264.7 cell in both 
NEW3 nanoemulsion treatments (0.024 mg/mL and 0.048 mg/mL). In 
addition, we observed significantly higher incorporation kinetics for the 
0.024 mg/mL treatment. As expected, for the control group, DHA levels 
were undetectable. 
Fig. 2. Raman spectra of nanoemulsion NEW3 at 25 ◦C, per-
formed after 0 (i), 365 (ii) and 730 (iii) days (a). Zoom of 
spectral regions 1200 – 1350, 1550 – 1800 and 2650 – 
3100 cm− 1, associated with δ_cis (=CH), δ_t (〖CH〗_2); cis, 
trans ν(C––C) and ν(=CH), ν(〖CH〗_2) vibrational modes, 
respectively (b), (c) and (d). The solid lines show the Lor-
entzian fits of the experimental data. Relative unsaturation (%) 
at time t = 0 days estimated from ratio between integrated 
intensities of bands at 1265/1300 cm− 1 (black), 1657/1300 
(dark gray), 3015/1300 (gray) and 3015/2850 cm− 1 (light 
gray) (e).   
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Fig. 3. In vitro experiments with RAW 264.7 macrophage cells. (A) Cell index in real time for NEW3 fish oil nanoemulsion; (B) Cell index in real time for NE-blank 
nanoemulsion; (C) Cell incorporation kinetics of cis-4,7,10,13,16,19 docosahexaenoic - DHA fatty acid. Legends: NEW3: fish oil nanoemulsion; NE-blank: white 
nanoemulsion without fish oil; T(1… 6): treatments with samples in different concentrations; t: time. The data were expressed with the mean ± SD of three repe-
titions. The ANOVA multiple comparison test was applied with the level of significance p ≤ 0.05. Different letters represent statistical differences *(p ≤ 0.05). 
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Fig. 3C demonstrates that the fatty acid DHA was effectively inter-
nalized by the cells in a concentration-dependent manner, as shown in 
the graph of the area under the curve. In this graph, the concentration of 
free DHA is clearly observed when the concentrations of 0.024 and 
0.048 mg/mL of the nanoemulsion are compared. This is important 
evidence that demonstrates the ability of the NEW3 nanoemulsion to 
associate with biological membranes, a property that will be needed for 
in vivo absorption experiments. 
The immunological modulating effects of polyunsaturated fatty acids 
(PUFAs) occur when these molecules are effectively incorporated into 
cell membrane phospholipids. Investigations of the kinetics of PUFA 
incorporation into cultured cells are models used to explore the ab-
sorption, metabolism and molecular effects of these fatty acids. To this 
end, the experimental conditions used for cell cultures are physiologi-
cally important in terms of the concentration of fatty acid in the culture 
medium. 
Macrophages play a fundamental role in the onset of inflammation 
and are metabolically active, being distributed in the connective tissue 
that influences local and systemic functions [58]. The circulation of 
monocytes can vary after their production in the bone marrow [8]. In 
this interval of cell renewal, cells incorporate fatty acids (DHA and EPA) 
in their newly synthesized phospholipid membranes. 
In the literature, studies demonstrate that diets with EPA and DHA 
fatty acids depending on the position in the dietary triacylglycerols 
(TAG) of fish oil may have an influence on their incorporation into 
cellular phospholipids and on the activity of phagocytic cells [60]. In the 
study by Adolph et al. [61], RAW 264.7 macrophage cells supplemented 
with docosahexaenoic acid (DHA) increase the rate of phagocytosis and 
the bactericidal capacity of macrophages. The authors support the idea 
of supplementing immunocompromised individuals with PUFAs, as well 
as people suffering from chronic infections. 
It is important to note that these studies involve research on sup-
plementation with omega-3 PUFAs based on concentrations of fatty 
acids without nanotechnological apparatus. In the present study, fish oil 
was associated in a nanoemulsion (NEW3) with a physiologically rele-
vant 0.024 mg/mL (Fig. 3C) concentration, demonstrating kinetically 
the incorporation of DHA in less time in macrophage cells, so it is 
therefore a promising approach to modulating immune responses and 
attenuating the inflammatory signaling in in vivo models. 
The absorption of nanoparticles by cells is a two-step process: first, a 
binding step on the cell membrane and then a second step of internali-
zation. Therefore, the ability of nanostructures to adhere to biological 
membranes is one of the most desired objectives when thinking about 
nanocarriers for the transport of lipophilic compounds. 
Fig. 4. Time of gastric emptying in two experimental models in the gastrointestinal system. (A): animals fasting 12 h; (B) fed animals; (C): in vivo bioluminescence of 
the stomach region; (D): area under the curve of the experimental groups. Legends: XDIR: fluorescent lipophilic marker (1,1′-dioctadeciltetramethyl indo-
tricarbocyanine iodide); NEW3: fish oil nanoemulsion; SD: Standard deviation. t: time, color scale: min. = 31, max. = 130. The data are plotted according to the 
mean ± SD of three repetitions. The bidirectional multiple comparison test - ANOVA was applied with the level of significance *p ≤ 0.05. 
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3.6. In vivo experiments 
3.6.1. Stomach emptying time 
After experiments with the cytotoxicity tests and the incorporation of 
nanoemulsion in cells, we performed the first study in animals to eval-
uate the gastric emptying time of NEW3 in the gastrointestinal tract 
(TGI) in an in vivo imaging experiment. This experimental approach was 
previously published by our research group [19] with the aim of 
studying the emptying time of lipophilic molecules in the stomach, 
which can be correlated with the time it takes for samples to reach the 
intestine and be absorbed. The samples were marked with a sensitive 
fluorophore - XDIR. 
In Fig. 4A it is possible to observe the results of the average radiance 
of the kinetics of the marked samples and of the fluorophore collected 
from the region of the animals’ stomach for the different treatments in 
the fasting model. The graph shows that both treatments with fish oil 
(FO) and XDIR are kept in the stomach for longer periods, compared to 
NEW3, which has a faster gastric emptying time. In Fig. 4B the results of 
the kinetics of the samples marked for the model with the fed animals 
are shown, and again we found that the treatment with the NEW3 
nanoemulsion showed similar characteristics to that observed in the 
fasting model, with a fast gastric emptying time. Important to highlight 
here that we are measuring the in vivo XDIR fluorochrome. The physical 
NE stability cannot be measured by this technique. However, based on 
the colloidal stability results, we can see that the hydrodynamic diam-
eter (Fig. 1A) is kept stable for all time, even in conditions where the pH 
is reduced (Fig. 1D). So, based on this observation, we can suggest that 
the pH is not a determining variable for nanodroplet stability. 
In Fig. 4C, there is a qualitative assessment of the bioluminescence of 
the experimental groups in the stomach region after 24 h. In this image, 
the retention of samples in the stomach region is evident for the groups 
XDIR and FO, while no fluorescent signal is observed for NEW3. These 
results demonstrate that necessarily the fish oil carried in NEW3 nano-
emulsion was more advantageous for the oral biodistribution of this 
compound in the TGI. 
It is interesting to note that when we analyzed the AUC of the groups 
(Fig. 4D), we observed that for both conditions, fasting and fed animals, 
NEW3 provides shorter gastric emptying times compared to the other 
experimental groups with significant differences (p ≤ 0.05) when 
compared to free FO. These data point to the capacity of this nanocarrier 
to improve the bioavailability of FO, which is a highly lipophilic com-
pound, regardless of the dietary condition, which is an important 
characteristic for this type of nutritional supplementation for oral 
administration. 
It is also important to note that the FO samples were kept in the 
stomach for at least 24 h, while NEW3 was removed from the stomach 
very quickly (~ 75 % in two hours). These data suggest that fish oil 
retention in the stomach can be significantly reduced. This finding may 
be useful to improve possible gastric discomforts associated with oral 
intake of conventional fish oil capsules, a problem that is often cited by 
many consumers. 
In addition, this study has a strong correlation with the bioavail-
ability of PUFAs [62] and can be used as possible evidence of absorption. 
The absorption dynamics of NEW3 is not significantly altered when the 
animals are fasting or fed; however, the dynamics of conventional FO is 
slightly shifted to the left in the group of animals fed, confirming that 
this type of nutrient is strongly influenced by the quality of diet. 
A critical point in the PUFA literature always demonstrates that DHA 
and EPA are not effectively absorbed when administered orally. The 
bioavailability of these compounds can be affected by other nutritional 
aspects, mainly related to the fat content in the diet [63,64]. In addition, 
supplementation of FO in its conventional form is generally an un-
pleasant experience, which can impair an individual’s adherence to this 
practice. 
The study by Dey et al. [65] shows the comparison of intestinal ab-
sorption of fish oil rich in EPA and DHA in a nanoemulsion (NE) and a 
conventional emulsion (CE) using the in-situ model of single-pass 
perfusion (infusion of single pass) in rats. In this work, the NE signifi-
cantly improved the absorption of lipids compared to the CE in the small 
intestine of rats, reaching a percentage above 45 % for NE compared to 
20 % of the CE in the rate of absorbed lipids. 
In the upper intestinal tract, water-soluble lipases are present in 
excessive amounts. Thus, the greater the available lipid and water 
interface, the greater the number of lipases that will be able to catalyze 
the hydrolysis of lipids at the lipid-water interface. This interface is 
increased by the peristaltic movements of the intestine; thus, for a 
certain period of time, greater amounts of fatty acids can be absorbed 
[66]. 
These observations may explain the fact that lipid droplets in the 
form of nanodroplets can be rapidly hydrolyzed, approaching the lipid 
absorption site with greater speed, where they pass through the water 
layer more easily. They can in turn be absorbed by passive diffusion in 
the intestinal epithelia [67,68]. 
In this context, the NEW3 nanoemulsion differential is based on the 
transport of fish oil tricialglycerols (TAG) in an aqueous medium where 
the absorption process of fat-soluble nutrients (DHA and EPA) is ach-
ieved in the intestinal cells. In addition, the formulation contains BBS oil 
that protects the nanoemulsion from possible oxidative effects (Fig. 2) 
and presents concentrations of physiologically biocompatible DHA and 
EPA that can facilitate absorption in cell membranes (Fig. 3). 
The advantages of oral supplements offered by means of a nano-
emulsion can facilitate the solubilization of fatty acids, as well as 
improving the absorption potential, thus providing a better fluidity of 
the membrane [67]. In this sense, the key point of the present study 
presents the FO transported in a stable long-term NEW3 system, with 
acceptable concentrations and easily absorbed in membrane phospho-
lipids, therefore, minimizing the exacerbated production of high po-
tential inflammatory mediators. 
3.6.2. LPS-induced sepsis model 
After the NEW3 nanoemulsion absorption experiments, we carried 
out the first inflammatory experiment in order to evaluate the inflam-
matory modulation provided by the supplementation with the NEW3 
nanoemulsion and the conventional FO. For this, the experimental ani-
mals received a diet with different treatments for 21 days. 
Soon after this period, the animals were submitted to an inflamma-
tory challenge where they received a subcutaneous injection of LPS, 
used to simulate Sepsis. For this challenge, we measured neutrophil 
infiltration using the in vivo imaging technique at 2 h and 24 h after 
induction, and the survival profile of experimental mice up to 48 h is 
shown in Fig. 5. 
Fig. 5A shows the infiltration of neutrophils after 2 h in animals 
treated with NEW3, FO and sunflower oil (SO). Sunflower oil supple-
mentation was used because of its composition in omega-6 poly-
unsaturated fatty acids. In the graph we can see that this time interval 
was not enough to produce significant differences between the experi-
mental groups. However, when measuring after 24 h (Fig. 5B), we 
observed a significant increase in neutrophil infiltration in animals 
treated with SO compared to the other groups. As this oil is a source of 
omega-6 PUFAs that will produce pro-inflammatory eicosanoids, we 
hoped that this supplementation could increase inflammation. Fig. 5C 
shows the detected signals of fluorescence in vivo in the different 
experimental groups. 
In Fig. 5D, we present the survival profile. As can be seen, 20 % of the 
experimental mice in the control group survived until the end of the 
trial, while 80 % of the mice treated with NEW3 and FO survived. SO 
treated animals had a survival rate of 60 %. The survival profile between 
these groups was significantly different: interestingly, after the first two 
hours of the infection induced by sepsis there was a significant death 
rate among the animals in the control group that did not receive treat-
ment, even not observing differences in neutrophil infiltration, leaving 
only 1 surviving animal 48 h after the end of the test. 
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In in vivo models, sepsis is achieved when the animal has an infection 
and demonstrates toxicity or other signs of the disease, and when un-
treated it can quickly die [68]. The high survival rate for the groups 
treated with NEW3 and FO may signal a protective effect against the 
induced bacterial infection. In this work, we selected an inflammatory 
initiator that triggers the inflammatory process through different bio-
logical pathways. We used lipopolysaccharide (LPS), a component of the 
cell wall of Gram-negative bacteria, which is a potent activator of neu-
trophils and monocytes [69]. In our experimental conditions, after cell 
activation, a cytokine storm is released and LPS sepsis is installed [70]. 
We use this model because FO supplementation has been used to prevent 
sepsis in patients with severe high-risk burns in the ICU [2]. 
Omega-3 fatty acids DHA and EPA compete with omega-6 fatty acids, 
that is, with arachidonic acid (AA) to produce anti-inflammatory me-
diators in the COX-2 pathway. In this enzymatic competition, DHA and 
EPA will significantly reduce the extent of inflammation [71]. It is 
important to note that both groups containing fish oil (NEW3 and FO) 
had interesting survival profiles, signaling that this type of supplemen-
tation can be useful to improve the survival rates of patients in the ICU. 
In the study by Svahn et al. [72], animals fed an omega-3 fatty acid 
diet had a longer survival time and a lower bacterial load compared to 
those fed with saturated fatty acids, after sepsis induced by S. aureus. 
These results highlight that the associations between nutritional factors, 
lipid profile and survival are of considerable interest in interventions for 
serious bacterial infections. 
Some studies have demonstrated lipid emulsions containing fish oil 
for severe septic patients as part of parenteral nutrition [73]. However, 
there are not yet enough studies of fish oil-based nanoemulsions as part 
of the oral diet for prevention or therapeutic measure for sepsis. We 
tested the NEW3 nanoemulsion where we observed promising prophy-
lactic effects for sepsis in an in vivo experimental model. Therefore, to 
further explore the inflammatory modulation of NEW3 supplementa-
tion, we performed the second inflammatory challenge, as demonstrated 
in the next item. 
3.6.3. Formalin-induced inflammation model paw edema 
The second challenge of in vivo inflammation investigated was the 
formalin-induced paw edema model, as shown in Fig. 6. In Fig. 6A, we 
observed the kinetics of the volume of the paw edema in the different 
experimental groups. Only the NEW3 group showed a significant 
reduction in edema volume (p ≤ 0.05) during the experiments. In all 
other experimental treatments, a significant increase in edema volume 
was observed. Fig. 6B represents the area under the curve (AUC) of the 
experimental data. 
Edema induction can be done with agents that lead to a local in-
flammatory response [74,75]. for this experiment we used Formalin 
(FM) which is a highly reactive compound that can produce cross-links 
between cellular proteins [75,76]. In addition, this molecule can reduce 
cell glutathione activity, leading to the generation of reactive oxygen 
species (ROS) [77]. ROS in turn damage cellular structures, thus 
Fig. 5. Inflammatory challenge LPS-induced sepsis. (A) average radiance of neutrophil inflation after 2 h; (B) average radiance of neutrophil inflation after 24 h; (C) 
qualitative image of fluorescence after 2 h and 24 h; (D) Survival profile (%) up to 48 h after sepsis induction. All animals received a dose of 2 mg/Kg of LPS. The 
control group during the supplementation period was not treated, receiving PBS. Both the NEW3 and FO groups were treated with a daily dose of fish oil in the 
sample of 100 mg/Kg (containing 50 mg/Kg of DHA and 10 mg/Kg of EPA). The sunflower oil group was treated with a daily dose of sunflower oil of 100 mg/Kg 
(containing 58 mg/Kg of linoleic acid). Legends: NEW3: fish oil nanoemulsion; FO: fish oil; SO: sunflower oil; t: time. The data are plotted according to the 
mean ± SD, the multiple comparison test ANOVA, Tukey test was applied adopting the significance level of *p ≤ 0.05. 
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triggering a local inflammatory process. 
As shown in Fig. 6A, the volumes of the animals’ paw edema were 
less pronounced for the group treated with the NEW3 nanoemulsion, 
compared to the other groups. More intense edema was also observed in 
animals supplemented with sunflower oil (SO) (Fig. 6B), confirming the 
data found in the first inflammatory challenge. The animals supple-
mented with fish oil (FO) showed similar results to the control group, FM 
and SO, with significant differences in the percentage of increased paw 
volume when compared to the NEW3 treatment (Fig. 6A). 
This event also allows the intensity of the nociceptive response to be 
analyzed in two phases: acute and late, both with different properties. 
The initial phase comprises from zero to five minutes; it is called non- 
inflammatory (neurogenic) pain and reflects central pain. The second 
starts 15− 30 min after the injection; it is called inflammatory pain and is 
characterized by local inflammation from the release of inflammatory 
mediators such as prostaglandins (PGE2) and hyperalgesia [74,75]. 
It is noted that in the time interval characterized by inflammatory 
pain a milder decreasing curve was observed for the group treated with 
NEW3 compared to the other groups (Fig. 6A), indicating here a bio-
logical effect of the NEW3 nanoemulsion dosage containing 100 mg/Kg 
of fish oil with 50 mg/Kg of DHA and 10 mg/Kg of EPA. 
There was no significant effect of the FO group in the same amounts 
administered in relation to the control group, FM and SO, 15 min after 
the injection of Formalin. These results suggest that the dosage of fish oil 
was more effective in the NEW3 nanoemulsion to reduce formalin- 
induced paw edema, pointing here to anti-inflammatory activity. 
The reduction of edema in mice is one of the most suitable proced-
ures for screening anti-inflammatory agents [74,75]. This assay is 
considered an appropriate experimental model for the evaluation of the 
acute anti-inflammatory effect of various agents [78]. Specifically, for 
fish oil, some studies demonstrate the anti-inflammatory and analgesic 
effects evaluated by the paw edema method [79]. However, they are 
studies using samples of conventional oils and not nanoemulsified. 
In this experiment, we also measured the concentration of PGE2 in 
the tissues of the paw collected from the experimental groups, PGE2 is a 
prostaglandin characterized as a biomarker of inflammation. During 
edema a cascade of biochemical events occurs and propagates an in-
flammatory response involving the migration of various blood leuko-
cytes to the site of infection or edema. Leukocytes drive the release of 
mediators at the site of inflammation, which may include lipid media-
tors such as prostaglandins (PG) and leukotrienes (LT) [10,11,17]. 
As shown in Fig. 6C, this biomarker presented a slight reduction in 
animals treated with NEW3 compared to animals in the FM group; 
however, this reduction was not statistically significant. No significant 
difference was observed when comparing all other experimental groups. 
These results indicate that the inflammatory challenge, by the injection 
of an initiator such as formalin, induced the expression of PGE2 at 
detectable levels that were not differentiated in the statistical tests. 
Fig. 6. Paw edema inflammation model induced with formalin. (A) percentage of the increase in the paw volume of the experimental groups; (B) area under the 
experimental data curve; (C) concentration of prostaglandin PGE2 (pg/mL) in the tissue of the animals’ right paws. All animals were induced with an injection of 2.5 
% formalin, except for the saline control group, which was induced with 0.9 % NaCl. The saline control group and the formalin group during the supplementation 
period were not treated, receiving only PBS. Both the NEW3 and FO groups were treated with a daily dose of fish oil in the sample of 100 mg/Kg (containing 50 mg/ 
Kg of DHA and 10 mg/Kg of EPA). The sunflower oil group was treated with a daily dose of sunflower oil of 100 mg/Kg (containing 58 mg/Kg of linoleic acid). 
Legends: NEW3: fish oil nanoemulsion; FO: fish oil; SO: sunflower oil; t: time; PGE2: prostaglandin series 2. Data are plotted according to the mean ± SD, the 
multiple comparison test ANOVA, Tukey test was applied adopting the significance level of p ≤ 0.05. Different letters represent statistical differences *(p ≤ 0.05). 
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However, the small decrease in PGE2 expression, together with the 
significant reduction in paw edema in animals supplemented with 
NEW3 nanoemulsion, may indicate possible biological protection in the 
response of the acute phase of an inflammatory process. 
3.6.4. Hematological and histological analysis 
The results of the hematological analysis for the erythrogram, total 
platelet count and leukogram of the experimental groups of the paw 
edema model are shown in Table 2. The data analysis shows that there 
were no significant changes (p ≤ 0.05) in the blood cells in the analyzed 
parameters among the groups tested. 
Hematological evaluation is an important analysis for determining 
the physiological profile of animals and is commonly used for in-
vestigations in response to genetically induced infectious diseases or by 
dietary and pharmacological therapies. In addition, it helps in the cre-
ation of reference values that reflect a given health condition of the 
animal [80]. However, establishing reference ranges for rodents re-
quires greater accuracy, since there are several important guidelines that 
must be considered that range from the animal’s genetic variation to the 
environmental conditions in which these animals live [81]. The values 
expressed for hematological parameters for NEW3 showed similarities 
with data from the literature [81,82]. 
When measuring the masses of the livers for the different experi-
mental groups of the paw edema model, there was only a slight 
(p ≤ 0.05) divergence in the mean of the NEW3 group compared to the 
saline control group. However, this mean did not differ significantly 
(p ≤ 0.05) among the other groups, and no major macroscopic visual 
changes were observed in the experimental groups (Supplementary 
Fig. S5). 
In the histological analysis of the livers of the animals submitted to 
the different treatments, we observed that for the FM group (formalin) 
there were microscopic changes in the structure of the liver tissue, with 
inflammatory foci and brief indications of hemorrhages and hepatic 
necrosis, as expected. For the saline control group there were no changes 
in the tissue structure: the FO (fish oil) group had few inflammatory 
infiltrates, mainly around vessels; the SO (sunflower oil) group had 
small inflammatory foci with changes in the structure of the liver tissue. 
For the NEW3 group, small inflammatory infiltrates were observed, but 
there was no pathology in the tissue. 
All of these outcomes are important observations, demonstrating 
that the treatment with NEW3 was well tolerated and providing re-
sponses that did not affect the quality of the animals’ health during the 
study period investigated. 
3.6.5. Clinical aspects of treatments 
In order to know if the different treatments would be toxic to the 
animals during the period of supplementation that preceded the in-
flammatory challenges, the evaluation of some clinical parameters was 
carried out, and we organized these results in Fig. 7. Fig. 7A and 7B 
shows the average of feed consumption per group for the two experi-
mental lots destined for the sepsis and paw edema models, respectively. 
It is noted that there was a gradual increase in feed consumption per 
group for animals representative of the 1 st experimental batch, while in 
the 2nd batch a constant was observed between the groups with dif-
ferences (p ≤ 0.05) in consumption, and a significant decrease (p ≤ 0.05) 
for the SO group. 
As explained at other times, the animals received an oral supple-
mentation of NEW3, FO and SO for 21 days, before the inflammatory 
challenges, so this is an important period in which to evaluate the 
possible toxicological activities as well as the clinical aspects of these 
treatments. In Fig. 7C and D, the animals’ body mass averages are pre-
sented; no differences were observed in the change in the animals’ 
weights in relation to the control group (Fig. 7C), and the initial weight 
range of the animals in the first batch was around 22.0–25.0 g. 
For the animals obtained for the second batch, the initial weight 
range for each group was: saline control (16–20 g), FM (20–21 g), SO 
(22–23 g), FO (23–26 g) and NEW3 (26–31 g). This grouping was 
necessary since the batch of animals supplied did not present uniformity, 
but it can be observed that during the experiment the means of the 
groups were still within these ranges Fig. 7D. 
The data referring to individual weight gain (Fig. 7E and F) and the 
feed efficiency determined by means of the food efficiency coefficient 
(CEA) (Fig. 7G and H) showed that, for each treatment, regardless of 
batches, significant differences were not observed between groups. The 
animal’s metabolism can be affected by different causes and also by 
environmental conditions. It can be noted that the treatments with the 
NEW3 nanoemulsion and the other experimental groups for 21 days in 
two different periods did not affect the main murinometric measures, 
demonstrating the reproducibility of the experimental method of oral 
supplementation of these formulations and also indicating biocompati-
bility of the tested dosage of the formulation NEW3 in an animal model. 
4. Conclusion 
In conclusion, we observed that the NEW3 nanoemulsion developed 
in this study showed long-term colloidal and chemical stability. NEW3 
was useful in reducing the gastric emptying time of lipophilic com-
pounds such as fish oil and, therefore, can be an important formulation 
to reduce gastric discomfort related to oral intake of fish oil capsules. 
NEW3 proved to be an interesting oral nanocarrier for administering fish 
oil and showed results with protective effects on animals when tested in 
two different inflammatory experiments. The inflammation models and 
the experimental method of supplementation were reproducible and 
offered similar results. 
Table 2 
Erythrogram and Leukogram of Balb/c mice submitted to different treatments after induction of the paw edema inflammation model.  
Erythrogram 
Parameter Unity Control FM SO FO NEW3 
RBC x106/μL 14.16 ± 1.48 12.68 ± 1.21 14.69 ± 0.88 7.04 ± 5.27 5.98 ± 4.93 
HGB g/dL 20.2 ± 2.11 16.78 ± 2.49 20.77 ± 1.67 9.92 ± 7.32 13.85 ± 14.39 
HCT % 53.54 ± 5.75 47.61 ± 4.20 54.68 ± 4.82 25.55 ± 19.01 19.96 ± 18.38 
PTL x103/μL 786.6 ± 159.18 1350.66 ± 736.40 1040.71 ± 202.25 977.66 ± 369.85 1688.66 ± 2619.93 
Leukogram 
Parameter Unity Control FM SO FO NEW3 
WBC x103/μL 3.98 ± 2.19 7.42 ± 6.38 4.07 ± 1.28 2.82 ± 1.77 5.13 ± 4.05 
W-SCC x103/μL 2.34 ± 1.28 3.77 ± 2.97 2.1 ± 1.21 1.92 ± 0.81 3.32 ± 2.17 
W-MCC x103/μL 1.48 ± 0.79 3.23 ± 3.36 1.83 ± 0.41 1450 ± 369.68 2.48 ± 2.03 
W-LCC x103/μL 0.16 ± 0.11 0.42 ± 0.55 0.13 ± 0.18 125 ± 95.74 0.36 ± 0.27 
Control: Saline; FM: Formalin; SO: sunflower oil; FO: Fish oil; NEW3: Fish oil nanoemulsion; RBC: total red blood cell count; HGB: hemoglobin concentration; HCT: 
hematocrit percentage; PTL: platelets count; WBC: total white blood cell count; W-SCC: absolute small white blood cell count - lymphocytes; W-MCC: intermediate cell 
count – monocytes; W-LCC: large cell count – neutrophils. 
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Fig. 7. Murinometric measurements of adult female balb / c animals submitted to oral treatments with NEW3, FO and SO supplementation. (A) and (B) feed 
consumption by group (g); (C) and (D) Body Mass (g); (E) and (F) Individual weight gain (g/d); (G) and (H) food efficiency coefficient - CEA (g/d). The animals were 
supplemented with the following dosages in two different periods for 21 days: The saline control group and the formalin group were not treated, receiving only PBS. 
The NEW3 and FO group were treated with a daily dose of fish oil in the sample of 100 mg/Kg (containing 50 mg/Kg of DHA and 10 mg/Kg of EPA). The sunflower oil 
group was treated with a daily dose of sunflower oil of 100 mg/Kg (containing 58 mg/Kg of linoleic acid). (A, C, E and G) refers to the first experimental batch for the 
Sepsis model, (B, D, F and H) refers to the second experimental batch for the paw edema model. Legends: NEW3: fish oil nanoemulsion; FO: fish oil; SO: sunflower 
oil; t: time. The data are plotted according to the mean ± SD, the multiple comparison test ANOVA, Tukey test was applied adopting the significance level 
of *p ≤ 0.05. 
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P. Mascarenhas, J. Moraes, Leite JRSA, C.-S. Jiang, R.B. Azevedo, J.P.F. Longo, 
Self-nanoemulsifying drugdelivery systems improve oral absorption and 
antischistosomal activity of epiisopiloturine, Nanomedicina (Lond) 13 (7) (2018) 
689–702, https://doi.org/10.2217/nnm-2017-0308. 
[20] H. Zhang, M.A. Shahbazi, P.V. Almeida, H.A. Santos, Chapter 3, mucus as a barrier 
for biopharmaceuticals and drug delivery systems, in: J. das Neves, B. Sarmento 
(Eds.), Mucosal Delivery of Biopharmaceuticals, 2014, pp. 59–97, https://doi.org/ 
10.1007/978-1-4614-9524-6_3. ISBN 978-1-4614-9524-6. 
[21] M. Vancamelbeke, S. Vermeire, The intestinal barrier: a fundamental role in health 
and disease, Expert Rev. Gastroenterol. Hepatol. 11 (9) (2017) 821–834, https:// 
doi.org/10.1080/17474124.2017.1343143. 
[22] C. Solans, I. Solé, Nano-emulsions: Formation by low-energy methods, Curr. Opin. 
Colloid Interface Sci. 17 (5) (2012) 246–254, https://doi.org/10.1016/j. 
cocis.2012.07.003. 
[23] V. Monge-Fuentes, L.A. Muehlmann, J.P.F. Longo, J.R. Silva, M.L. Fascineli, 
P. Souza, F. Faria, I.A. Degterev, A. Rodriguez, F.P. Carneiro, C.M. Lucci, 
P. Escobar, R.F.B. Amorim, R.B. Azevedo, Photodynamic therapy mediated by acai 
oil (Euterpe oleracea Martius) in nanoemulsion: a potential treatment for 
melanoma, J. Photochem. Photobiol. B, Biol. 166 (2017) 301–310, https://doi.org/ 
10.1016/j.jphotobiol.2016.12.002. 
[24] FAO - Food and Nutrition Paper 91, Fats and Fatty Acids in Human Nutrition 
Report of an Expert Consultation, Food and Agriculture Organization of the United 
Nations, Rome, 2010, pp. 1–180. ISBN 978-92-5-106733-8. 
[25] International Society for the Study of Fatty Acids and Lipids – ISSFAL. PUFA 
Recommendations, 2019 [on-line] https://www.issfal.org/pufa-recommendations. 
access date: October 21. 
[26] World Health Organization, Population Nutrient Intake Goals for Preventing Diet- 
related Chronic Diseases [on-line] https://www.who.int/nutrition/topics/5_po 
pulation_nutrient/en/index13.html. access date: October 21, 2019. 
[27] Food Suplements: Baseline Document for Regulatory Discussion, National 
HealthSurveillance Agency. General Food Management (GGALI), 2017 june 
[online]. 
[28] S.K. Brar, M. Verma, Measurement of nanoparticles by light-scattering techniques, 
Trac Trends Anal. Chem. 30 (1) (2011) 4–17, https://doi.org/10.1016/j. 
trac.2010.08.008. 
[29] ISO 22412 - International Organization for Standardization, Norma 
InternacionalParticle Size Analysis - Dynamic Light Scattering (DLS) [on-line], 
https://www.iso.org/obp/ui/#iso:std:iso:22412:ed-1:v1:en. access date: January 
05, 2017. 
[30] S. Honary, F. Zahir, Effect of zeta potential on the properties of nano-drug delivery 
systems - a review (Part 1), Trop. J. Pharm. Res. 12 (2) (2013) 255–264, https:// 
doi.org/10.4314/tjpr.v12i2.19. 
[31] D.S. Santos, Development and evaluation of the antioxidant potential in vitro of 
nanoformulations containing oil from the fruit Orbignya phalerata Martius. 
Dissertation of Master’s Degree in Nanoscience and Nanobiotechnology, University 
of Brasília, Brasília, 2015, pp. 1–114. 
[32] S.M. Dordevic, T.S. Adulovic, N.A.D. Cekic, D.V. Randelovic, M.M. Savic, D. 
R. Krajisnik, J.R. Milic, S.D. Savic, Experimental design in formulation of diazepam 
nanoemulsions: physicochemical and pharmacokinetic performances, J. Pharm. 
Sci. 102 (11) (2013) 4159–4172, https://doi.org/10.1002/jps.23734. 
[33] ISO 5509, International Standard, Animal and Vegetable Fats and Oils -Preparation 
of Methyl Esters of Fatty Acids, 2, International Organization for Standardization, 
2000, p. 30. Reference number ISO 5509:2000(E). 
[34] M.C. Milinsk, M. Matsushita, J.V. Visentainer, C.C. Oliveira, N.E. Souza, 
Comparative analysis of eight esterification methods in the quantitative 
determination of vegetable oil fatty acid methyl esters (FAME), J. Braz. Chem. Soc. 
19 (8) (2008) 1475–1483, https://doi.org/10.1590/S0103-50532008000800006. 
[35] A. Kotani, M. Watanabe, K. Yamamoto, F. Kusu, H. Hakamata, Determination of 
eicosapentaenoic, docosahexaenoic, and arachidonic acids in human plasma by 
HighPerformance liquid chromatography with electrochemical detection, Anal. 
Sci. 32 (9) (2016) 1011–1014, https://doi.org/10.2116/analsci.32.1011. 
[36] P. Salm, P.J. Taylor, K. Kostner, Simultaneous quantification of total 
eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by 
high-performance liquid chromatography–tandem mass spectrometry, Biomed. 
Chromatogr. 25 (6) (2011) 652–659, https://doi.org/10.1002/bmc.1496. 
D.S. Santos et al.                                                                                                                                                                                                                                
Biomedicine & Pharmacotherapy 133 (2021) 110980
17
[37] Brazil Law No. 11,794, of October 8, 2008, Procedures for the Scientific use of 
Animals, 2017. Access date: December 21Available in: http://www.mdic.gov.br/in 
dex.php/legislacao/154-leis/1336-lei-n-11-794-de-8-de-outubro-de-2008. 
[38] Ministry of Science, Technology, Innovations and Communications, Normative 
resolutions - CONCEA. Standards and Technical Guidelines - 3rd Edition - Brasilia, 
2016. September 26th. 
[39] Guidance on the Operation of the Animals (Scientific Procedures) Act 1986, 2017. 
Access date: December 21Available in: https://www.gov.uk/guidance/guidance- 
on-the-operation-ofthe-animals-scientific-procedures-act-1986. 
[40] Y. Aratani, Myeloperoxidase: Its role for host defense, inflammation, and 
neutrophil function, Arch. Biochem. Biophys. 640 (2018) 47–52, https://doi.org/ 
10.1016/j.abb.2018.01.004. 
[41] S. Gross, S.T. Gammon, B.L. Moss, D. Rauch, J. Harding, J.W. Heinecke, L. Ratner, 
D.P. Worms, Imagem de bioluminescência da atividade da mieloperoxidase in vivo, 
Nat. Med. 15 (2009) 455–461, https://doi.org/10.1038/nm.1886. 
[42] J. Sawynok, A. Reid, Peripheral interactions between dextromethorphan, ketamine 
and amitriptyline on formalin-evoked behaviors and paw edema in rats, Pain 102 
(1–2) (2003) 179–186, https://doi.org/10.1016/s0304-3959(02)00373-1. 
[43] C.S. Nery, I.L. Pinheiro, G.S. Muniz, D.A.A. Vasconcelos, S.P. França, 
E. Nascimento, Murinometric evaluations and feed efficiency in rats from reduced 
litter during lactation and submitted or not to swimming exercise, Rev. Bras. Med. 
Esporte. 17 (1) (2011) 49–55, https://doi.org/10.1590/S1517- 
86922011000100010. 
[44] R.M. Walker, E.A. Decker, D.J. Mcclements, Physical and oxidative stability of fish 
oil nanoemulsions produced by spontaneous emulsification: effect of surfactant 
concentration and particle size, J. Food Eng. 164 (2015) 10–20, https://doi.org/ 
10.1016/j.jfoodeng.2015.04.028. 
[45] M. Nejadmansouri, S.M.H. Hosseini, M. Niakosari, G.H. Yousefi, M.T. Golmakani, 
Physicochemical properties and oxidative stability of fish oil nanoemulsions as 
affected by hydrophilic lipophilic balance, surfactant to oil ratio and storage 
temperature, Colloids Surf. A Physicochem. Eng. Asp. 506 (2016) 821–832, 
https://doi.org/10.1016/j.colsurfa.2016.07.075. 
[46] T. Amnuaikit, Formulation development and preparation of fish oil liposome by 
using high pressure homogenizer for food supplement product, Asian J. Pharm. Sci. 
11 (1) (2016) 126–127, https://doi.org/10.1016/j.ajps.2015.11.094. 
[47] S. Honary, F. Zahir, Effect of zeta potential on the properties of nano-drug delivery 
systems - a review (Part 2), Trop. J. Pharm. Res. 12 (2) (2013) 265–273, https:// 
doi.org/10.4314/tjpr.v12i2.20. April. 
[48] Aragão N.M. de, C. Veloso MC da, Andrade J.B. de, Validation of chromatographic 
methods - an experiment using HPLC and Green Chemistry in methylxanthines 
determination, Química Nova 32 (9) (2009) 2476–2481, https://doi.org/10.1590/ 
S0100-40422009000900043. 
[49] K. Czamara, K. Majzner, M.Z. Pacia, K. Kochan, A. Kaczor, M. Baranska, Raman 
spectroscopy of lipids: a review, J. Raman Spectrosc. 46 (1) (2015) 4–20, https:// 
doi.org/10.1002/jrs.4607. 
[50] C.J. Barrow, C. Nolan, Y. Jin, Stabilization of highly unsaturated fatty acids and 
delivery into foods, Lipid Technol. 19 (5) (2007) 108–111, https://doi.org/ 
10.1002/lite.200600037. 
[51] P.B.M.C. Derogis, A.B. Chaves-Fillho, S. Miyamoto, Characterization of hydroxy 
and hydroperoxy polyunsaturated fatty acids by mass spectrometry, in: 
A. Trostchansky, H. Rubbo (Eds.), Bioactive Lipids in Health and Disease. Advances 
in Experimental Medicine and Biology, vol 1127, Springer, Cham, 2019, https:// 
doi.org/10.1007/978-3-030-11488-6_2. 
[52] D. Borchman, M.C. Yappert, Age-related lipid oxidation in human lenses, Invest. 
Ophthalmol. Vis. Sci. 39 (6) (1998) 1053–1058. Doi:. 
[53] L.E. Jamieson, A. Li, K. Faulds, D. Graham, Ratiometric analysis using Raman 
spectroscopy as a powerful predictor of structural properties of fatty acids, R. Soc. 
Open Sci. 5 (12) (2018), 181483, https://doi.org/10.1098/rsos.181483. 
[54] H. Sadeghi-Jorabchi, R.H. Wilson, P.S. Belton, J.D. Edwards-Webb, D.T. Coxon, 
Quantitative analysis of oils and fats by Fourier transform Raman spectroscopy, 
Spectrochim. Acta A. 47 (9-10) (1991) 1449–1458, https://doi.org/10.1016/0584- 
8539(91)80236-C. 
[55] Ds Santos, Jpf Longo, Rb Azevedo, Mcp Costa, Pen Souza, Al. Camara, Antioxidant 
Nanoformulation from Babassu Fruit Oil (Orbignya phalerata Martius) and its 
Process of Obtaining, v.2458, Industrial Property Magazine, Brazil, 2018, p. 254. 
Patent deposit under number BR 10 2016 017598 4 registered at INPI – the 
National Institute of Industrial Property. 
[56] C. Wijesundera, C. Ceccato, P. Watkins, P. Fagan, B. Fraser, N. Thienthong, 
P. Perlmutter, Docosahexaenoic acid is more stable to oxidation when located at 
the sn-2 position of triacylglycerol compared to sn-1(3), J. Am. Oil Chem. Soc. 85 
(2008) 543–548, https://doi.org/10.1007/s11746-008-1224-z. 
[57] W.M. Cruvinel, D.M. Júnior, J.A.P. Araújo, T.T.T. Catelan, A.W.S. Souza, N. 
P. Silva, L.E.C. Andrade, Fundamentals of innate immunity with emphasis on 
molecular and cellular mechanisms of inflammatory response, Bras. J. Rheumatol. 
50 (4) (2010), 434-61. PMID: 21125178. 
[58] Y. Oishi, I. Manabe, Macrophages in inflammation, repair and regeneration, Int. 
Immunol. 30 (11) (2018) 511–528, https://doi.org/10.1093/intimm/dxy054. 
[59] R. Gorjão, A.K. Azevedo-Martins, H.G. Rodrigues, F. Abdulkader, M. Arcisio- 
Miranda, J. Procopio, R. Curi, Comparative effect of DHA and EPA on cell function, 
Pharmacol. Ther. 122 (2009) 56–64, https://doi.org/10.1016/j. 
pharmthera.2009.01.004. 
[60] S. Kew, E.S. Gibbons, F. Thies, G.P. McNeill, P.T. Quinlan, P.C. Calder, The effect of 
feeding structured triacylglycerols enriched in eicosapentaenoic or 
docosahexaenoic acids on murine splenocyte fatty acid composition and leucocyte 
phagocytosis, Br. J. Nutr. 90 (2003) 1071–1080, https://doi.org/10.1079/ 
BJN2003996. 
[61] S. Adolph, H. Fuhrmann, J. Schumann, Unsaturated fatty acids promote the 
phagocytosis of P. aeruginosa and R. equi by RAW264.7 macrophages, Curr. 
Microbiol. 65 (6) (2012) 649–655, https://doi.org/10.1007/s00284-012-0207-3. 
[62] P. Schönfeld, L. Wojtczak, Short-and medium-chain fatty acids in energy 
metabolism: the cellular perspective, J. Lipid Res. 57 (6) (2016) 943–954, https:// 
doi.org/10.1194/jlr.R067629. 
[63] M. Cholewski, M. Tomczykowa, M. Tomczyk, A comprehensive review of 
chemistry, sources and bioavailability of Omega-3 fatty acids, Nutrients 10 (1662) 
(2018) 2–33, https://doi.org/10.3390/nu10111662. 
[64] M.B. Galuch, F. Carbonera, T.F.S. Magon, R. Silveira, P.D.S. Santos, J.S. Pizzo, O. 
O. Santos, J.V. Visentainer, Quality assessment of Omega-3 supplements available 
in the brazilian market, J. Braz. Chem. Soc. 29 (3) (2018) 631–638, https://doi. 
org/10.21577/0103-5053.20170177. 
[65] T.K. Dey, S. Ghosh, M. Ghosh, H. Koley, P. Dhar, Comparative study of 
gastrointestinal absorption of EPA & DHA rich fish oil from nano and conventional 
emulsion formulation in rats, Food Res. Int. 49 (1) (2012) 72–79, https://doi.org/ 
10.1016/j.foodres.2012.07.056. 
[66] E. Bauer, S. Jakob, R. Mosenthin, Principles of physiology of lipid digestion, Asian- 
Australas J. Anim. Sci. 18 (2) (2005) 282–295, https://doi.org/10.5713/ 
ajas.2005.282. 
[67] Y. Lu, J. Qi, W. Wu, Absorption, disposition and pharmacokinetics of 
nanoemulsions, Curr. Drug Metab. 13 (4) (2012) 396–417, https://doi.org/ 
10.2174/138920012800166544. 
[68] D.J. McClements, Y. Li, Structured emulsion-based delivery systems: controlling 
the digestion and release of lipophilic food components, Adv. Colloid Interface Sci. 
159 (2) (2010) 213–228, https://doi.org/10.1016/j.cis.2010.06.010. 
[69] J.A. Nemzek, K.M.S. Hugunin, M.R. OPP, Modeling Sepsis in the laboratory: 
merging sound science with animal well-being, Comp. Med. 58 (2) (2008) 
120–128. PMID: 18524169, PMCID: PMC2703167. 
[70] H. Fang, R.A. Pengal, X. Cao, L.P. Ganesan, M.D. Wewers, C.B. Marsh, 
S. Tridandapani, Lipopolysaccharide-induced macrophage inflammatory response 
is regulated by SHIP, J. Immunol. 173 (1) (2004) 360–366, https://doi.org/ 
10.4049/jimmunol.173.1.360. 
[71] J.S. Kang, Y.J. Jeon, S.-K. Park, K.-H. Yang, H.M. Kim, Protection against 
lipopolysaccharide-induced sepsis and inhibition of interleukin-1β and 
prostaglandin E2 synthesis by silymarin, Biochem. Pharmacol. 67 (1) (2004) 
175–181, https://doi.org/10.1016/j.bcp.2003.08.032. 
[72] P.C. Calder, Marine omega-3 fatty acids and inflammatory processes: effects, 
mechanisms and clinical relevance, Biochim. Biophys. Acta 1851 (2015) 469–484, 
https://doi.org/10.1016/j.bbalip.2014.08.010. 
[73] S.L. Svahn, M.A. Ulleryd, L. Grahnemo, M. Ståhlman, J. Borén, S. Nilsson, J. 
O. Jansson, M.E. Johansson, Dietary Omega-3 fatty acids increase survival and 
decrease bacterial load in mice subjected to Staphylococcus aureus-induced sepsis, 
Infect. Immun. 84 (4) (2016) 1205–1213, https://doi.org/10.1128/IAI.01391-15. 
[74] K. Mayer, W. Seeger, Fish oil-containing lipid emulsions in patients with sepsis, 
Crit. Care 14 (2) (2010), https://doi.org/10.1186/cc8882, 128;1-2. 
[75] A. Soyocak, H. Kurt, D.T. Cosan, F. Saydam, I.U. Calis, U.K. Kolac, Z.O. Koroglu, 
I. Degirmenci, F.S. Mutlu, H.V. Gunes, Tannic acid exhibits anti-inflammatory 
effects onformalin-induced paw edema model of inflammation in rats, Hum. Exp. 
Tox. 38 (11) (2019) 1–6, https://doi.org/10.1177/0960327119864154. 
[76] A.B. Salinas-Abarca, S.H. Avila-Rojas, P. Barragán-Iglesias, J.B. Pineda-Farias, 
V. GranadosSoto, Formalin injection produces long-lasting hypersensitivity with 
characteristics of neuropathic pain, Eur. J. Pharmacol. 797 (15) (2017) 83–93, 
https://doi.org/10.1016/j.ejphar.2017.01.018. 
[77] S. Ortega-Atienza, C. Krawic, L. Watts, C. McCarthy, M.W. Luczak, A. Zhitkovich, 
20S immunoproteasomes remove formaldehyde-damaged cytoplasmic proteins 
suppressing caspase-independent cell death, Sci. Rep. 654 (7) (2017) 1–10, https:// 
doi.org/10.1038/s41598-017-00757-w. 
[78] Y. Saito, K. Nishio, Y. Yoshida, et al., Cytotoxic effect of formaldehyde with free 
radicals via increment of cellular reactive oxygen species, Toxicology 210 (2–3) 
(2005) 235–245, https://doi.org/10.1016/j.tox.2005.02.006. 
[79] K.R. Patil, U.B. Mahajan, B.S. Unger, S.N. Goyal, S. Belemkar, S.J. Surana, S. Ojha, 
C.R. Patil, Animal models of inflammation for screening of anti-inflammatory 
drugs: implications for the discovery and development of phytopharmaceuticals, 
Int. J. Mol. Sci. 20 (18) (2019) 1–38, https://doi.org/10.3390/ijms20184367. 
[80] J.N. Jacob, D.K. Badyal, Biological studies of turmeric oil, part 3: anti- 
inflammatory and analgesic properties of turmeric oil and fish oil in comparison 
with aspirin, Nat. Prod. Commun. 9 (2) (2014) 225–228, https://doi.org/10.1177/ 
1934578X1400900224. 
[81] K.E. O’Connell, A.M. Mikkola, A.M. Stepanek, et al., Hematopatologia murina 
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